SARS-CoV-2 (COVID-19, 2019-nCoV) Nucleoprotein antibody is in a phosphate saline buffer (0.01M, pH 7.2) containing 0.1% sodium azide preservative. No stabilizing proteins have been added.
Formulierung:
Liquid
Application Verdünnung:
Optimal dilutions for each application to be determined by the researcher.
Figure 1 Western Blot Validation with Human Recombinant Protein Loading: 50 ng per lane of human nucleocapsid recombinant protein. Antibodies: SARS-CoV-2 nucleocapsid, 35-580, 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-mouse IgG HRP conjugate at 1:5000 dilution. Lane 1: 1 µg/mL Lane 2: 2 µg/mL
Figure 2 ELISA Test Antibodies: SARS-CoV-2 Nucleocapsid antibody, 35-580. An ELISA was performed using human SARS-CoV-2 Nucleocapsid recombinant protein as coating antigen and the SARS-CoV-2 Nucleocapsid antibody, as the capture antibody. Secondary: Goat anti-mouse IgG HRP conjugate at 1:20000 dilution. Detection range is from 16 ng/mL to 1000 ng/mL.
Figure 3 ELISA Test Antibodies: SARS-CoV-2 Nucleocapsid antibody, 35-580. An ELISA was performed using human SARS-CoV Nucleocapsid recombinant protein as coating antigen and the SARS-CoV-2 Nucleocapsid antibody, as the capture antibody. Secondary: Goat anti-mouse IgG HRP conjugate at 1:20000 dilution. Detection range is from 8 ng/mL to 1000 ng/mL.
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
